Patients with pathogenic mutations in these RAD51 regulator genes, particularly RAD51C and RAD51D, have a higher risk of developing ovarian cancer [RAD51C, OR 8.3 (95% CI 5.43–12.48); RAD51D, OR 3.17 (95% CI 1.31–7.42)] (75). Here, RAD51D is linked to ovarian cancer.